- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Arcturus Therapeutics Holdings Inc (ARCT)
Arcturus Therapeutics Holdings Inc stock price live, this page displays NASDAQ ARCT stock exchange data. View the ARCT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Arcturus Therapeutics Holdings Inc real time stock price chart below.
What Is the Arcturus Therapeutics Holdings Inc Stock Price Today?
The Arcturus Therapeutics Holdings Inc stock price today is 8.87.
What Is the Stock Symbol for Arcturus Therapeutics Holdings Inc?
The stock symbol for Arcturus Therapeutics Holdings Inc is "ARCT."
What Stock Exchange Does Arcturus Therapeutics Holdings Inc Trade On?
Arcturus Therapeutics Holdings Inc is listed and trades on the NASDAQ stock exchange.
Is Arcturus Therapeutics Holdings Inc a Good Stock to Buy?
Determining whether Arcturus Therapeutics Holdings Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARCT quote. (ISIN: US03969T1097)
What Is the Arcturus Therapeutics Holdings Inc Stock Price Today?
The Arcturus Therapeutics Holdings Inc stock price today is 8.87.
What Is the Stock Symbol for Arcturus Therapeutics Holdings Inc?
The stock symbol for Arcturus Therapeutics Holdings Inc is "ARCT."
What Stock Exchange Does Arcturus Therapeutics Holdings Inc Trade On?
Arcturus Therapeutics Holdings Inc is listed and trades on the NASDAQ stock exchange.
Is Arcturus Therapeutics Holdings Inc a Good Stock to Buy?
Determining whether Arcturus Therapeutics Holdings Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARCT quote. (ISIN: US03969T1097)
8.87
+0.02(+0.23%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.55
8.95
52 wk Range
5.85
24.17
ARCT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.558.95
52 wk Range
5.8524.17
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ARCT Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
23.30
Upside
+162.68%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Arcturus Therapeutics Holdings Inc SWOT Analysis
mRNA Trailblaze | Arcturus Therapeutics leads with self-amplifying mRNA technology, potentially revolutionizing vaccine efficacy and safety profiles in a competitive market |
Financial Trajectory | Explore Arcturus' path to profitability, balancing strong liquidity with negative margins as it aims to capitalize on its innovative pipeline |
Strategic Alliances | Delve into Arcturus' partnership with CSL Seqirus, offering billions in potential milestones and global market access for its vaccine candidates |
Market Opportunities | Analyst targets range from $41 to $140, reflecting diverse views on Arcturus' potential in COVID-19, influenza, and emerging vaccine markets |
Arcturus Therapeutics Holdings Inc Earnings Call Summary for Q4/2025
- Arcturus reported Q4 2025 EPS of -$1.03 vs. $4.28 expected; revenue of $7.2M missed forecast of $232.52M by 96.9%, driving stock down 5.27% to $8.35.
- Revenue decline attributed to reduced collaboration income and program transitions to commercial phase; company maintains $232.8M cash position.
- Cash runway extends into Q2 2028, providing buffer as company focuses strategic efforts on rare disease clinical programs for future growth.
- CEO Payne reaffirmed commitment to rare disease programs despite disappointing results; upcoming quarters forecast continued negative EPS amid execution challenges.
- Key risks include ongoing revenue declines, high R&D expenses, commercial viability uncertainty, and potential regulatory hurdles for clinical programs.
Last Updated: 2026-03-03, 05:46 p/m
Read Full TranscriptCompare ARCT to Peers and Sector
Metrics to compare | ARCT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipARCTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.8x | −4.3x | −0.5x | |
PEG Ratio | −0.19 | 0.09 | 0.00 | |
Price/Book | 1.2x | 2.5x | 2.6x | |
Price / LTM Sales | 3.1x | 11.0x | 3.2x | |
Upside (Analyst Target) | 131.6% | 47.8% | 44.2% | |
Fair Value Upside | Unlock | 4.6% | 5.5% | Unlock |
Analyst Ratings
10 Buy
3 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 23.30
(+162.68% Upside)
Earnings
Latest Release
Mar 03, 2026
EPS / Forecast
-1.03 / 4.28
Revenue / Forecast
7.2M / 232.52M
People Also Watch
FAQ
What Is the Arcturus Therapeutics Holdings Inc (ARCT) Stock Price Today?
The Arcturus Therapeutics Holdings Inc stock price today is 8.87 USD.
What Stock Exchange Does Arcturus Therapeutics Holdings Inc Trade On?
Arcturus Therapeutics Holdings Inc is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Arcturus Therapeutics Holdings Inc?
The stock symbol for Arcturus Therapeutics Holdings Inc is "ARCT."
What Is the Arcturus Therapeutics Holdings Inc Market Cap?
As of today, Arcturus Therapeutics Holdings Inc market cap is 252.97M USD.
What Is Arcturus Therapeutics Holdings Inc's Earnings Per Share (TTM)?
The Arcturus Therapeutics Holdings Inc EPS (TTM) is -2.40.
When Is the Next Arcturus Therapeutics Holdings Inc Earnings Date?
Arcturus Therapeutics Holdings Inc will release its next earnings report on May 11, 2026.
From a Technical Analysis Perspective, Is ARCT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Arcturus Therapeutics Holdings Inc Stock Split?
Arcturus Therapeutics Holdings Inc has split 1 times.
How Many Employees Does Arcturus Therapeutics Holdings Inc Have?
Arcturus Therapeutics Holdings Inc has 109 employees.
What is the current trading status of Arcturus Therapeutics Holdings Inc (ARCT)?
As of Apr 20, 2026, Arcturus Therapeutics Holdings Inc (ARCT) is trading at a price of 8.87 USD, with a previous close of 8.85 USD. The stock has fluctuated within a day range of 8.55 USD to 8.95 USD, while its 52-week range spans from 5.85 USD to 24.17 USD.
What Is Arcturus Therapeutics Holdings Inc (ARCT) Price Target According to Analysts?
The average 12-month price target for Arcturus Therapeutics Holdings Inc is 23.30 USD, with a high estimate of 68 USD and a low estimate of 8 USD. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +162.68% Upside potential.
What Is the ARCT Premarket Price?
ARCT's last pre-market stock price is 8.59 USD. The pre-market share volume is 6,340.00, and the stock has decreased by -0.26, or -2.94%.
What Is the ARCT After Hours Price?
ARCT's last after hours stock price is 8.80 USD, the stock has decreased by -0.05, or -0.56%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.